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enrolled in this trial. All patients received abciximab before or in the cath-lab before start 
of the PCI. Half of the oatients had orior CPR and 2l3 were intubated on enrolment in the 
study. A 3-vessel disease was present in 72.5% of the patients. An occluded infan vessel 
(TIMI O/l flow) before PCI was obseved in 65%. The oatients were orosoectivelv followed 
N, Pts M/D,% RR M/D/R, % RR 
Tnl(+). Reverse 17 29 415 29 24 
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Trill (-), NO Reverse 996 0.1 1.0 (reference) 1.7 1 .O (reference) 
RR=relative risk: ‘=pcO.Ol compared to Tnl(-), no Reverse; #=p<O.O5 compared to 
Trill (-), Reverse 
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1196-106 Percutaneous Coronary Intervention During the Index 
Hospitalization Is Associated With Reduced Recurrent 
Myocardial Infarction and Improved Survival Following 
Thrombolytic Administration 
C. Michael Gibson, Juhana Karha, Sabina A. Murphy, Christopher P. Cannon, Robert P 
Giugliano. Elliott M. Antman. Eugene Braunwald, The TIMI Study Group, Brigham 8 
Women’s Hospital, Boston, MA 
Background: Recurrent myocardial infarction (reMI). remains a limitation of fibrinolytic 
therapy. We hypothesized that following fibrinolytic administration, performance of percu- 
taneous coronary intervention (PCI) during the index hospitalization is associated with 
lower rates of recurrent MI and death compared to conservative management. Methods: 
Performance of PCI thru hospital discharge and mortality up to 2 years were ascertained 
in the TIMI 4, 9A, 98, 106 and 17 acute Ml trials (n=20,043). Patients whose PCI fol- 
lowed a recurrent Ml (n=266) were included in the medical therapy arm. Results: PCI 
was performed in 21.4% of patients at a median of 4 days (IQ range l-6). In-hospital 
recurrent Ml occurred less frequently in patients treated with PCI vs. patients without PCI 
(1.6% vs. 4.5%, p<O.OOl). Mortality was also lower in patients treated with PCI 
(pc0.0001; Figure). Similar results were seen across the low, intermediate, and high TIMI 
risk scores (Figure). Both PCI and recurrent MI remained associated with 2 year mortality 
in a model adjusting for age, anterior MI. pulse on admission, and gender (PCI hazard 
ratio=0.51, p<O.OOl; recurrent Ml hazard ratio=l.95, p<O.OOl). Conclusion: Following 
thrombolytic administration, PCI during the index hospitalization was associated with a 
lower rate of in-hospital recurrent MI and improved 2 year survival. 
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1196-l 07 Prospective Study of Primary Percutaneous 
Intervention and Abciximab in Patients With ST 
Elevation Myocardial Infarction Complicated by 
Cardiogenic Shock 
Uwe Zevmer, Ulrich Tebbe, Michael W. Weber. Hans-Friedrich Vijhringer, Karl-Ludwig 
Neuhaus. for the ALKK Study Group, Klinikum Ludwigshafen, Ludwigshafen. Germany 
Background: Patients presenting with ST-elevation myocardial imfarction (STEMI) com- 
plicated by cardiogenic shock have a high mortality despite early interventional therapy. 
Antiplatelet therapy with potent GPllb/lllA inhibition with abciximab has been shown to 
reduce ischemic complications after PCI and improve outcome. Therefore we performed 
a prospective multicenter study to evaluate a routine strategy of primary percutaneous 
intervention (PCI) and adjunctive therapy with abciximab in patients with STEMI compli- 
cated by cardiogenic shock. Methods: Fourty patients with STEMI < 12 hrs. were 
. 
for 30-day outcome. Results: The intervention was successfull in 92.5% of the patients, 
60% had TIMI 3 flow after the PCI. A stent was implanted in 65 % of the patients.Major 
bleeding complications were observed in 5% of the patrents. The 30.day mortality rate 
was 42.5%. In patients 575 years (n=29) mortality was 24% whrle all but one (10111) of 
the patients > 75 years died. Conclusion: A routine strategy of primary PCI and adjunc- 
tive therapy with abciximab patients with STEMI complicated by cardiogenic shock is 
safe and associated with a high rate of successful1 interventions and seems to improve 
outcome rn patients 5 75. 
1196-108 Reduction in Hospital Mortality by First Day 
Percutaneous Coronary Intervention for Non-ST 
Elevation Myocardial Infarction in Diabetics: Results of 
the ACOS-Registry 
Anselm K. Gitt Rudolf Schiele, Harm Wienbergen, St&fen Schneider, Tobias Heer, Uwe 
Zeymer, Martin G. Gothvik, Jochen Senges, ACOS-Study-Group. Herzzentrum 
Ludwigshafen, Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg, 
Germany 
Background: Current studies have reported a reduction in mortality by first day PCI in 
patients (pts) with acute coronary syndromes (ACS) without persistent ST-elevation. 
Data on outcome of high risk diabetics with non-ST-elevation myocardial infarction 
(NSTEMI) in clinical practice do not yet exist. 
Methods: Since June 2000 consecutive pts with ACS have been enrolled into the ACOS- 
Registry in 154 hospitals in Germany. We analysed the impact of first day PCI in diabet- 
ics with NSTEMI on hospital outcome. 
Results: Out of 12154 consecutive patients with ACS, 4954 (41%) presented with 
NSTEMI, of whom 1567 (32%) were diabetics. First day PCI was performed in 31311567 
pts (20%). Determinants in favour of first day PCI were prior PCI / CABG (OR 2.13; 1.56. 
2.61). age < 70 years (OR 1.93; 1.47-2.52) and male gender (OR 1.47; 1 .lO-1.93). A 
determinant against first day PCI in diabetics was prior myocardial infarction (OR 0.51: 
0.35-0.74). 
After adjusting for differences in baseline characteristics and adjunctive therapy, first day 
PCI in diabetics with NSTEMI was associated with a 63% reductron of hospital mortality 
(OR 0.37,o.ia-0.75). 
Conclusion: Determinants for first day PCI in diabetics with NSTEMI were male gender, 
age c 70 years and prior PCI or CABG. First day PCI in acute NSTEMI was associated 
with a high 63% reduction of adjusted odds for hospital mortality. 
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1196-109 Improved Functional Status and Quality of Life After 
Invasive Management of Non-ST-Segment Elevation 
Acute Myocardial Infarction 
Mark J. Eisenberg, Flora F. Teng Muhammad R. Chaudhry Jose Ortiz, Louise Pilate, 
Jewish General Hospital/McGill Universrty, Montreal, PQ, Canada 
Background: While recent studies suggest that clinical outcomes may be improved by 
invasive management following non-ST-segment elevation acute myocardial infarction 
(AMI), it remains unclear whether functional status and quality of life (QOL) are affected 
by an invasive strategy. 
Methods: We randomized 63 patients to invasive vs. non-invasive management foltow- 
ing non-ST-segment elevation AMI. Functional status was assessed using maximal exar- 
cise endurance on a treadmill at 12.months and the Duke Activity Status Index (DASI) at 
both baseline and IP-months. QOL was assessed using the Seattle Angina Question- 
naire (SAQ) and the Medical Outcomes Study 36-Item Short-Form Health Status Survey 
(SF-36) at baseline and 1 P-months. 
Results: Patients were predominantly middle-aged men (56.3 il2.0 years, 61.4% male). 
Of the patients randomized to an invasive strategy, 76.6% received angiography. Of the 
patients randomized to the non-invasive strategy, 91 .I% received functional testing. 
Cumulative revascularization rates were similar in both groups (24.4% vs. 20.0% respec- 
tively). Maximal exercise endurance (set) at 12.months did not show a significant differ- 
ence between the two arms (652.1 vs. 556.7, P=NS). The invasive arm was found to 
have improved functional status by a mean difference of +6.6 (P=O.OZ) in DASI Score 
between IP-months and baseline. The invasive arm was also found to have improved 
QOL with the general health and physical functroning measures of the SF-36 showng a 
trend towards improved QOL (mean difference +6.7, P=O.lO, +13.2, P=O.lO, respec- 
tively). The SAQ angina1 stability and angina1 frequency measures showed a significant 
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tmprovement in the invasive arm (mean difference +29.5, P=O.Ol, 18.5, P~0.04, respec- 
tively) and a trend in SAQ treatment satisfaction measure (mean difference +19.2, 
P=O.O7). All other measures were similar between the two arms. 
Conclusions: Patients undergoing invasive management after non-ST-segment eleva- 
tion AMI show improved functional status and quality of life. 
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administrated ix. 40 mg. before the first dose of 0.75 MU. of SK and 1 mg/kg every 12 
hours for 5-7 days. Heparin was infused 1000 i.u.ihour for 46-96 hoursThree noninva- 
sive reperfusion criteria were used: 1Rapid cessation of the chest pain. 2Rapid 
decreasing of the ST segment elevations by more than 50% from the initial value. 
3Rapid increasing of the CK and CK-MB with a peak within the first 12 hrs. 
Results. The chest pain-thrombolysis time was 143+/-71 min in the preASENOX sub- 
group, significantly shorter that the inASENOX subgroup (176+/-76 min., p=O.O16) and 
the StSK one (171+/-76 min., p=O.Oll). The ratios of the coronary repsrfusion were 
61.2%. 76.1% and 60.7%, respectively (preASENOX vs StSK p=O.O67; inASENOX vs 
StSK p=O.O44). The inhospital mortalities were: 3.12% (preASENOX); 5.9% (inASENOX) 
and 10.4% (StSK)(non-significant differences). Neither stroke nor other major haemorag- 
ical events were registered in the three subgroups. Simptomatic hypotansion was benign 
and appeared more frequent in the preASENOX (32%) and inASENOX (34%) subgroups 
as compared to the StSK one (20%). 
Conclusions: 1. The preASENOX and inASENOX regimens are safe and lead toward a 
significant higher ratios of coronary repetfusion as compared to the StSK one. 2. Our 
data sugest a very low mortality in patients treated with the preASENOX regimenfurther 
investigation are needed for certify this attractive regimen. 
1196-110 Left Ventricular Ejection Fraction, Enzyme Release, and 
Stent Implantation Are Independent Predictors of Late 
Clinical Outcome After Late Opening of Infarct-Related 
Occlusion 
Francois Schiela Lionel Thebault, Pradip &woke, Pierre Legalery. Marie-France 
Seronde, Nicolas Meneveau, Jean-Pierre L. Bassand, University Hospital Jean-Mintoz, 
Besancon, France 
Background. The potential benefit of n-opening occluded infarct-related arteries (IRA) by 
percutaneous coronary intervention (PCI) is still debated. We assessed the immediate 
and long term clinical outcome of patients submitted to systematic attempt at IRA re- 
opening in a setting of a sub acute (a72 hours and cl0 days) myocardial infarction (Ml). 
Methods and Results. 199 consecutive patients matching these criteria were submitted 
to PCI and followed up for one year. Three endpoints were defined: (1) = composite of 
death, new Q wave MI, pert-procedural creatine kinase (CK) release >3 times the upper 
limit of normal, stroke, major bleeding or need for urgent revascularfsation at 30 days; (2) 
= one year survival without stroke, new MI or unstable angina; and (3) = endpoint #2 plus 
need for target lesion ravascularization. Reopening of the IRA was successful 159/199 
(60%) patients, with stem implantation in 99 (50%). Endpoint #f occurred in 16 (6%) 
patients; endpoint #2 in 30 (15%) and endpoint (3) in 44 (22%). Two year event free 
probability was 0.75*0.05 and 0.72a0.04 for endpoints #2 and #3 respectively. Left ven- 
tricular ejection fraction (LVEF) (odds ratio = 0.66 [0.79;0.94], p=O.OOl per additional per- 
cent of LVEF) and CK release (1.01 [l.OO;l.Ol], p=O.O4 per additional unit of CK 
released) were independent predictors for endpoint #2, with LVEF being the only inde- 
pendent predictor of endpoint #3. Lack of stem implantation (odds ratio = 0.26 [0.05:0.5]. 
p=O.O4) and CK release (1.01 [l.OO;l.Ol], p=O.O3) were independent predictors of death. 
Conclusion: Clinical outcome of patients submitted to systematic attempts to m-open 
occluded IRA in the setting defined in this study is mostly influenced by post Ml LV func- 
tion. Peri-procedural enzyme leakage and lack of stem implantation negatively influence 
late clinical outcome. 
1196-111 Antibody Levels Against Chlamydia Pneumoniae and 
Outcome of Roxithromycin Therapy: Results From a 
Substudy of the Randomized Antibiotic Therapy in 
Acute Myocardial Infarction (ANTIBIO) Trial 
Ralf Zahn, Ulrich Burckhardt, Ulrich Hoffler, Birait Frillinq, Jochen Senges. ANTIBIO 
study group, Herzzentrum, Ludwigshafen, Germany 
Background: Treatment with a macrolide antibiotic for patients (pts) with coronary artery 
disease may be only effective in pts with elevated antibody titers against Chlamydia 
pneumoniae(Cp). Methods: We therefore analyzed a pm-specified subgroup of the dou- 
ble-blind placebo controlled ANTIBIO study. Pts with an acute myocardial infarction were 
treated with either 300mgIod roxithromycin or pfacebolod for 6 weeks. A follow-up was 
performed at 12 months. In 160 out of 672 pts blood samples were analyzed for antibody 
titers (IgG, IgA and IgM by an enzyme linked immunoassay) against QI The combined 
endpoint (CE) was death, myocardial infarction, stroke, unstable angina, coronary bal- 
loon angioplasty or bypass surgery during 12 months follow up. Results: Positive anti- 
body titers against Cp were prevalent in 61.9% of pts for IgG, 55.6% for IgA and 1.9% for 
IgM. A CE occurred in 36% of pts being IgG seropositive compared to 32% in seronega- 
tive pts, and m 41% IgA seropositive versus 26% IgA seronegative pts (all p=ns). 61 pts 
received roxithromycin and 79 placebo. In the roxithromycin group a CE occurred in 42% 
of pts seropositive for IgG against Cpcompared to 26% in pts being seronegative (p=ns). 
In the placebo group CE occurred in 23% IgG seropositive pts versus 47% in seronega- 
tive pts (p=O.O25). No significant treatment effects were also seen according to preva- 
lence of IgA titers or in higher elevated titers. Conclusion: Neither seropositivity for C+I 
nor the amount of titer elevation was associated with a higher clinical event rate during 
12 month of follow up after an acute myocardial infarction. Treatment with roxithromycin 
did not influence the rate of clinical events, independently of presence or amount of anti- 
body titer elevation against Cp. 
1196-112 Safety and Efficacy of an Accelerated Streptokinase 
Regimen in Combination With Enoxaparin in the 
Prehospital Management of the ST Acute Myocardial 
Infarction (ASENOX-2) Study 
Gabriel Tatu-Chitoiu, Mircea Oprisan. Ovidiu Cismara, Rodica Marinescu, Ad& 
Marinescu, Radu Turcu, Maria Dorobantu, Spitalul Clinic de Urgenta. Bucuresti, 
Romania, Serviciul de Ambulanta, Bucuresti, Romania 
Background. Recent data suggest a similar efficacy of the standard Streptokinase (SK) 
regimen (1.5 M.U.160 min.) either in combination with Heparin or Enoxaparin in ST acute 
myocardial infarctton (STAMI). 
Objective Safety and efficacy of an accelerated SK regimen (0.75 M.U.00 min. 
repeated after 50 min. if no signs of coronary repertusion were detected) in combination 
with Enoxaparin was evaluated in the prehospital (preASENOX regimen) and the inhos- 
pital (inASENOX regimen) phase of STAMI and compared to the standard SK plus Hep- 
arin (StSK regimen). 
Methods. A group of 266 consecutive patients, thrombolised within the first 6 hours after 
the onset of STAMI was divided in three subgroups according to the mentioned regi- 
mens: preASENOX (64 pts.); inASENOX (67 pts) and StSK (135 pts.). Enoxaparin was 
1196-113 Erythropoietin Augments Cardiomyocyte Survival and 
Left Ventricular Function After Hypoxia 
Cvrus J. Parsa, Akio Matsumoto, G. Brant Walton, Jonathan S. Stamler, Walter J. Koch, 
Duke University, Durham, NC 
Background: Erythropoietin (EPO) may have effects beyond hematopoiesis such as 
prevention of neuronal apoptosis secondary to ischemia. We evaluated EPO protection 
in myocardial ischemia. Methods: H9c2 myoblasts were used to test EPCYs protection 
against hypoxia-induced apoptosis. Cells were pretreated with EPO (0.4 or lOU/ml) for 
24 hours (hrs) and exposed to hypoxia (95%b-5%CO,) for 12 hrs followed by 12 hrs of 
m-oxygenation, or H9c2 cells were treated with EPO after hypoxia and before re-oxygen- 
ation. Also, 250mM hjOs for 22 hrs was used as an apoptotic stimulus. Cells were 
stained and analyzed for % apoptotic nuclei. To apply our findings in viva. we used a 
model of myocardial infarction (Ml) in rabbits. Animals were randomized to receive a sin- 
gle dose of EPO (5000 units/kg) or saline or sham (no Ml). On post-operative day (POD) 
3, hemodynamic measurements were obtained. Hematocrits were drawn on POD 0, 1, 3, 
and 4. Hearts were harvested on POD 4 and infarct size quantified. Results: The graph 
shows that under all conditions tested, EPO prevented apoptosis in myoblasts.ln dvo, 3 
days after MI, EPO treated rabbits exhibited improved LV function, including contractility 
(~~0.05) and exhibited smaller infarct size. Protective effects were seen without 
increased hematocrit. Conclusions: EPO augmented myocyte survival after ischemia in 
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vitroand in viva, reduced infarct size and reversed ventricular dysfunction post-MI. Thus, 
EPO may offer novel protection for myocardial ischemia. 
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869-1 Influence of Smoking on Manifestation and Clinical 
Outcome of Acute ST Elevation Myocardial Infarction in 
Clinical Practice: Results of the ACOS Registry 
Christina Meisenzahl Anselm K. Gin, Rudolf Schiele. Harm Wienbergen. Tobias Heer. 
Martin G. Gottwik, Heruentrum Ludwigshafen, Ludwigshafen, Germany, Klinikum 
Niimberg Sod. Ntimberg, Germany 
Background: Subgroup-analysis of large randomised trials with selected patients have 
shown a lower mortalitv after ST Elevation Mvocardial Infarction (STEMI) in smokers 
I  
compared to nonsmokers. Little data exist on the differences in outcome of STEMI 
between smokers and nonsmokers in clinical practice. 
Methods: Since June 2000 consecutive patients (pts) with acute coronary syndrome 
(STEMI, Non-ST Elevation Myocardial Infarction and unstable angina) have been 
